Search

The aim of this paper was to estimate fermentation kinetic parameters to develop a mathematical model of the bioethanol production under magnetic field effect. Thus, a non-structured mathematical model was developed considering three non-lineal kinetic models typically known as Levenspiel, Aiba, Jerusalimsky, which take into account inhibitory effects of the high product concentration on yeasts. The non-lineal differential equations system solution was carried out by MatLab software using the Runge-Kutta fourth-order multivariable method. This method was improved through a replication scheme coupled with Newton-Raphson method modified with a damping Broyden parameter. Experimental data on substrate consumption, biomass formation and ethanol production were collected at magnetic field intensities (H) of 414, 796 and 1216 A/cm during 16 h of fermentation. Consequently, the adjusted model for biomass, consumed substrate and bioethanol produced allowed us to correlate fermentation kinetic parameters with the magnetic field. The best result was observed when Jerusalimsky model modified with a magnetic field parameter was considered, because the RMSD order and R-square correlation coefficient were around 10−3 and higher than 0.95, respectively. These results are important to understand the phenomenological behavior of this unconventional bioprocess and be helpful to further sensibility analysis and scale up of the bioethanol production assisted by electromagnetic field. Copyright © 2016 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Liposomal encapsulation of tuberculostatic drugs can potentially increase their therapeutic index. The incorporation of isoniazid, pyrazinamide, rifampicin, ethionamide, and streptomycin in extruded distearoylphosphatidylcholine/cholesterol liposomes designed for administration through inhalation was evaluated. Ethionamide and rifampicin were incorporated during lipid film formation, whereas solutions of the remaining drugs were used to hydrate preformed lipid bilayers. Final drug to lipid ratios around 0.3 were achieved for isoniazid and pyrazinamide, and mean vesicle diameters varied from 286 to 329 nm. No expressive drug leakage or mean vesicle diameter changes occurred during 3 weeks. No significant incorporation was achieved for streptomycin, ethionamide, and rifampicin. [ABSTRACT FROM AUTHOR]